CLLS52 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Alemtuzumab

Filter by location:

Los Angeles, California1 trial

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

University of California, Los Angeles (UCLA) - Medical Center

Phase 1/2

Chicago, Illinois1 trial

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

The University of Chicago Medical Center (UCMC)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.